» Authors » Toomas Toomsoo

Toomas Toomsoo

Explore the profile of Toomas Toomsoo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 10
Citations 107
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Kals M, Reigo A, Teder-Laving M, Vaht M, Nikopensius T, Metspalu A, et al.
Mov Disord Clin Pract . 2025 Feb; PMID: 40019135
Background: Dopaminergic neuron depletion in the substantia nigra (SN) and the pathological aggregation of α-synuclein are the neuropathological hallmarks of Parkinson's disease (PD). Objectives: This study aimed to investigate the...
2.
Nurm M, Reigo A, Annilo T, Toomsoo T, Noukas M, Nikopensius T, et al.
Eur J Hum Genet . 2024 Dec; PMID: 39674827
Population-based biobanks enable genomic screening to support initiatives that prevent disease onset or slow its progression and to estimate the prevalence of genetic diseases in the population. Wilson's disease (WD)...
3.
Bril V, Berkowicz T, Szczudlik A, Nicolle M, Bednarik J, Hon P, et al.
Muscle Nerve . 2024 Nov; 71(1):43-54. PMID: 39506903
Introduction/aims: Prospective, randomized, controlled trials of intravenous immunoglobulin (IVIG) maintenance therapy in myasthenia gravis (MG) are lacking. In this trial, we evaluated the safety and efficacy of caprylate/chromatography-purified IVIG; (IGIV-C)...
4.
Rump A, Ratas K, Lepasepp T, Suurvali J, Smolander O, Gross-Paju K, et al.
Scand J Immunol . 2024 Mar; 98(2):e13283. PMID: 38441379
Multiple sclerosis (MS) is an inflammatory autoimmune disorder of the central nervous system and the leading cause of progressive neurological disability in young adults. It decreases the patient's lifespan by...
5.
Bril V, Szczudlik A, Vaitkus A, Rozsa C, Kostera-Pruszczyk A, Hon P, et al.
Neurology . 2022 Oct; 100(7):e671-e682. PMID: 36270895
Background And Objectives: Myasthenia gravis (MG) is an autoimmune disease characterized by dysfunction at the neuromuscular junction. Treatment frequently includes corticosteroids (CSs) and IV immunoglobulin (IVIG). This study was conducted...
6.
Nogueira R, Qureshi M, Abdalkader M, Martins S, Yamagami H, Qiu Z, et al.
Neurology . 2021 Mar; 96(23):e2824-e2838. PMID: 33766997
Objective: To measure the global impact of COVID-19 pandemic on volumes of IV thrombolysis (IVT), IVT transfers, and stroke hospitalizations over 4 months at the height of the pandemic (March...
7.
Randver R, Davel K, Toomsoo T
Neurocase . 2019 Jul; 25(3-4):80-90. PMID: 31262224
An increasing amount of evidence is showing the therapeutic effects of rTMS on PD-related non-motor functions neuroanatomically linked to the DLPFC. This presents an ongoing need to apply an optimal...
8.
Toomsoo T, Liepelt-Scarfone I, Berg D, Kerner R, Pool A, Kadastik-Eerme L, et al.
Ultrasound Med Biol . 2018 Nov; 45(1):122-128. PMID: 30482710
Substantia nigra (SN) hyper-echogenicity (SN+) describes an enlargement (>90th percentile) of the area of echogenicity at the anatomic site of the SN in the midbrain detected by transcranial sonography. This...
9.
Toomsoo T, Randver R, Liepelt-Scarfone I, Kadastik-Eerme L, Asser T, Rubanovits I, et al.
Psychiatry Res Neuroimaging . 2017 Sep; 268:45-49. PMID: 28865346
Despite advances in diagnostics and clinical recognition, depressive symptoms in Parkinson's disease (PD) exceeding normal limits remain effectively untreated. In this study, we report on the prevalence and severity of...
10.
Toomsoo T, Liepelt-Scarfone I, Kerner R, Kadastik-Eerme L, Asser T, Rubanovits I, et al.
J Ultrasound Med . 2015 Nov; 35(1):17-23. PMID: 26589647
Objectives: Substantia nigra hyperechogenicity is a promising biomarker for Parkinson disease (PD). Substantia nigra hyperechogenicity has previously been established as a useful diagnostic criterion in several European and Asian patient...